CASP9 Knockout DLD-1 Polyclonal Cells are a CRISPR/Cas9-edited polyclonal cell population with targeted disruption of the CASP9 gene in the DLD-1 human colorectal adenocarcinoma line. This loss-of-function model comprises a mixed pool of cells containing diverse edits, reflecting a population-level knockout without clonal isolation. The polyclonal format provides a practical tool for studying caspase-9 function in apoptosis and signaling assays.
The DLD-1 cell line originates from a colorectal adenocarcinoma and exhibits microsatellite instability along with mutations in APC, TP53, KRAS, and PIK3CA. These alterations perturb growth, survival, and apoptotic pathways, making DLD-1 a widely used model for colorectal cancer research. Introducing the CASP9 knockout in this background enables targeted investigation of intrinsic apoptosis dependency within a clinically relevant mutational context.
CASP9 encodes caspase-9, the initiator caspase of the intrinsic apoptotic pathway. Mitochondrial cytochrome c release triggers apoptosome assembly with APAF1, leading to procaspase-9 recruitment and activation. Active caspase-9 cleaves and activates executioner caspases-3 and -7, which process key death substrates such as PARP1 and lamin A/C. Upstream, BCL-2 family proteins (BCL-2, BAX, BAK) regulate cytochrome c release, while p53 induces pro-apoptotic factors. Caspase-9 activity is inhibited by XIAP and relieved by SMAC/DIABLO.
In DLD-1 cells, which harbor TP53 mutations and dysregulated BCL-2 family members, the intrinsic apoptosis pathway is often impaired, contributing to chemoresistance. Loss of caspase-9 function in this genetic background allows systematic assessment of the reliance of colorectal cancer cells on mitochondrial apoptosis. The knockout model facilitates discovery of alternative cell death mechanisms and can be used to identify vulnerabilities that may be exploited for targeted therapy.
This polyclonal knockout product supports diverse applications such as apoptosis signaling studies, investigation of chemoresistance, and drug screening for apoptosis sensitizers. Key assays include Western blotting for cleaved caspases, annexin V/PI staining, cytochrome c release analysis, caspase activity measurements, and cell viability tests. The polyclonal format offers a convenient alternative to monoclonal lines for functional population studies. For technical inquiries, contact Ascent Research.
